4.96
-0.03 (-0.50%)
| 前收盘价格 | 4.98 |
| 收盘价格 | 5.05 |
| 成交量 | 162,349 |
| 平均成交量 (3个月) | 234,534 |
| 市值 | 183,803,248 |
| 价格/销量 (P/S) | 66.02 |
| 股市价格/股市净资产 (P/B) | 56.83 |
| 52周波幅 | |
| 利润日期 | 10 Jun 2025 - 25 Jun 2025 |
| 营业利益率 (TTM) | -4,013.86% |
| 稀释每股收益 (EPS TTM) | -1.98 |
| 季度收入增长率 (YOY) | -1.50% |
| 总债务/股东权益 (D/E MRQ) | 2.23% |
| 流动比率 (MRQ) | 4.51 |
| 营业现金流 (OCF TTM) | -61.24 M |
| 杠杆自由现金流 (LFCF TTM) | -43.65 M |
| 资产报酬率 (ROA TTM) | -88.08% |
| 股东权益报酬率 (ROE TTM) | -186.24% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 看跌 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看跌 | 混合的 | |
| 股票 | Anteris Technologies Global Cor | - | - |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.25 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Value |
| 内部持股比例 | 4.04% |
| 机构持股比例 | 49.10% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| L1 Capital Pty Ltd | 31 Dec 2024 | 2,788,683 |
| Sio Capital Management, Llc | 31 Dec 2024 | 2,370,000 |
| Regal Partners Ltd | 31 Dec 2024 | 1,293,861 |
| One68 Global Capital, Llc | 31 Dec 2024 | 288,914 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 31 Mar 2025 | 公告 | Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV |
| 21 Mar 2025 | 公告 | Anteris Reports One-Year Patient Outcomes for DurAVR® THV |
| 12 Mar 2025 | 公告 | Anteris Reports 2024 Financial Results and Provides Corporate Update |
| 28 Feb 2025 | 公告 | Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合